Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Psych Congress Network

Advertisement

Advertisement

Featured

a caregiver speaks with a doctor
News
Caregivers Confirm Usability of Schizophrenia Cognition Rating Scale
11/14/2024
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving...
11/14/2024
Psych Congress Network
An illustrated picture shows two cartoon doctors, one holding up a magnifying glass to a cartoon brain.
Conference Coverage
Flexible Dosing of Esketamine Nasal Spray Effective Over Long-Term
11/12/2024
Analysis of a long-term extension study of flexibly dosed esketamine nasal spray, in combination with an oral antidepressant, found durable long-term efficacy and safety of the treatment whether dosed weekly, every other week, or every 4...
Analysis of a long-term extension study of flexibly dosed esketamine nasal spray, in combination with an oral antidepressant, found durable long-term efficacy and safety of the treatment whether dosed weekly, every other week, or every 4...
Analysis of a long-term...
11/12/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
Jonathan Meyer, MD
Videos
Unpacking Negative Symptoms, Medication Adverse Effects, and Emerging Schizophrenia Treatments
11/11/2024
Jonathan Meyer, MD, offers his clinical insights on schizophrenia management.
Jonathan Meyer, MD, offers his clinical insights on schizophrenia management.
Jonathan Meyer, MD, offers his...
11/11/2024
Psych Congress Network
Thomas L. Schwartz, MD
Q&As
How Psychiatrists Can Address Sleep-Wake Disorders Effectively
11/09/2024
Thomas L. Schwartz, MD, shares exclusive insights from his session on sleep-wake issues presented at the 2024 NEI Fall Congress.
Thomas L. Schwartz, MD, shares exclusive insights from his session on sleep-wake issues presented at the 2024 NEI Fall Congress.
Thomas L. Schwartz, MD, shares...
11/09/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
Stephen M. Stahl
Conference Coverage
At the NEI Fall Congress, Leading Faculty Reflect on the Evolution of Psychiatry and What the Future May Hold
11/08/2024
The 2024 Neuroscience Education Institute (NEI) Fall Congress commenced with opening remarks from Andrew J. Cutler, MD, Chairman, and the highly anticipated keynote address from Stephen M. Stahl, MD, PhD, DSc (Hon.), Chairman Emeritus.
The 2024 Neuroscience Education Institute (NEI) Fall Congress commenced with opening remarks from Andrew J. Cutler, MD, Chairman, and the highly anticipated keynote address from Stephen M. Stahl, MD, PhD, DSc (Hon.), Chairman Emeritus.
The 2024 Neuroscience Education...
11/08/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
Desiree Matthews
Schizophrenia Conference Insights
New Class of Medication Offers Innovative Treatment for Schizophrenia Symptoms
11/07/2024
Watch these exclusive insights with Desiree Matthews, PMHNP-BC, to learn how this novel treatment could reshape the landscape of care for adults living with schizophrenia.
Watch these exclusive insights with Desiree Matthews, PMHNP-BC, to learn how this novel treatment could reshape the landscape of care for adults living with schizophrenia.
Watch these exclusive insights...
11/07/2024
Psych Congress Network
NEI Fall Congress 2024
Conference Coverage
Medication Management, Care Enhancements Under the Spotlight at the 20th Annual NEI Fall Congress
11/07/2024
The 20th annual NEI Fall Congress provides a space—both in person and online—where leading minds in psychiatry share current and emerging treatment strategies with the next generation of mental health care professionals.
The 20th annual NEI Fall Congress provides a space—both in person and online—where leading minds in psychiatry share current and emerging treatment strategies with the next generation of mental health care professionals.
The 20th annual NEI Fall...
11/07/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
Adults Who Smoke Have More Chronic Pain, Use More Opioids
News
Adults Who Smoke Have More Chronic Pain, Use More Opioids
11/07/2024
Rates of chronic pain, prescription opioid use, and severe work limitations rise with the number of cigarettes smoked daily, according to study results published in the American Journal of Preventive Medicine.
Rates of chronic pain, prescription opioid use, and severe work limitations rise with the number of cigarettes smoked daily, according to study results published in the American Journal of Preventive Medicine.
Rates of chronic pain,...
11/07/2024
Psych Congress Network
Patient survey
News
Patient Survey Identifies Barriers to TD Treatment
11/06/2024
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive...
11/06/2024
Psych Congress Network
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
depression stock photo
News
Add-on Lumateperone Eases MDD in Patients With Inadequate Antidepressant Response
11/04/2024
Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with MDD with inadequate response to previous antidepressant therapy, according to a poster...
Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with MDD with inadequate response to previous antidepressant therapy, according to a poster...
Adjunctive treatment with the...
11/04/2024
Psych Congress Network

Advertisement

Advertisement

Advertisement

From the Newsrooms

a caregiver speaks with a doctor
News
Caregivers Confirm Usability of Schizophrenia Cognition Rating Scale
11/14/2024
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving...
11/14/2024
Psych Congress Network
Desiree Matthews
Schizophrenia Conference Insights
New Class of Medication Offers Innovative Treatment for Schizophrenia Symptoms
11/07/2024
Watch these exclusive insights with Desiree Matthews, PMHNP-BC, to learn how this novel treatment could reshape the landscape of care for adults living with schizophrenia.
Watch these exclusive insights with Desiree Matthews, PMHNP-BC, to learn how this novel treatment could reshape the landscape of care for adults living with schizophrenia.
Watch these exclusive insights...
11/07/2024
Psych Congress Network
Patient survey
News
Patient Survey Identifies Barriers to TD Treatment
11/06/2024
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive...
11/06/2024
Psych Congress Network
depression stock photo
News
Add-on Lumateperone Eases MDD in Patients With Inadequate Antidepressant Response
11/04/2024
Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with MDD with inadequate response to previous antidepressant therapy, according to a poster...
Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with MDD with inadequate response to previous antidepressant therapy, according to a poster...
Adjunctive treatment with the...
11/04/2024
Psych Congress Network
Marc Agronin
Videos
Implementing Alzheimer Disease Prevention Practices
11/02/2024
Dr Marc Agronin discusses some easy prevention strategies for Alzheimer disease following his Psych Congress 2024 session "A New Era for Alzheimer’s Disease: Prevention, Early Diagnosis, Effective Intervention."
Dr Marc Agronin discusses some easy prevention strategies for Alzheimer disease following his Psych Congress 2024 session "A New Era for Alzheimer’s Disease: Prevention, Early Diagnosis, Effective Intervention."
Dr Marc Agronin discusses some...
11/02/2024
Psych Congress Network
Conference presenter
News
Olanzapine/Samidorphan Demonstrates Favorable Safety Profile in 4-Year Open-Label Study
11/01/2024
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination...
11/01/2024
Psych Congress Network
Michelle Martel, PhD
Q&As
When It Comes to ADHD in Women, There's Still So Much to Learn
10/31/2024
Michelle Martel, PhD, shares insights from her session on ADHD in women presented at the 2024 Psych Congress.
Michelle Martel, PhD, shares insights from her session on ADHD in women presented at the 2024 Psych Congress.
Michelle Martel, PhD, shares...
10/31/2024
Psych Congress Network
Andrew Penn
Q&As
Psychedelics: New Research, Regulations, and Horizons
10/30/2024
"Psychedelic therapies must continue to be researched so that perhaps, someday with their help, we will be able to help our patients live their best lives," Andrew Penn, PMHNP-BC.
"Psychedelic therapies must continue to be researched so that perhaps, someday with their help, we will be able to help our patients live their best lives," Andrew Penn, PMHNP-BC.
"Psychedelic therapies must...
10/30/2024
Psych Congress Network
Jo Hughes
Q&As
Unpacking the Pressing Challenges of Polypharmacy in Psychiatry
10/30/2024
Jo Hughes, DMSc, PA-C, CAQ-PSY, discusses the complexities of polypharmacy in psychiatry and the balance between medication management and patient safety.
Jo Hughes, DMSc, PA-C, CAQ-PSY, discusses the complexities of polypharmacy in psychiatry and the balance between medication management and patient safety.
Jo Hughes, DMSc, PA-C, CAQ-PSY,...
10/30/2024
Psych Congress Network
Beau Kilmer, PhD
Q&As
Psychedelic Policy and Market Considerations
10/28/2024
Dr Kilmer discusses the psychedelic market in the United States, policy on both state and local levels, and the role of the federal government in regulation.
Dr Kilmer discusses the psychedelic market in the United States, policy on both state and local levels, and the role of the federal government in regulation.
Dr Kilmer discusses the...
10/28/2024
Psych Congress Network

Quizzes

Pop quiz written on a blackboard with white chalk
Expert Insights Quiz
LAIs and Telehealth Psychiatric Care
10/24/2024
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
10/24/2024
Psych Congress Network
Four people ponder with question marks over their heads
Quiz
Adult ADHD Diagnosis Rates
10/23/2024
Take the quiz to test your knowledge!
Take the quiz to test your knowledge!
Take the quiz to test your...
10/23/2024
Psych Congress Network
Jonathan Meyer
Quiz
How do muscarinic acetylcholine receptor activators differ from traditional antipsychotic treatments?
10/23/2024
How do muscarinic acetylcholine receptor activators differ from traditional antipsychotic treatments? Take the quiz to find out!
How do muscarinic acetylcholine receptor activators differ from traditional antipsychotic treatments? Take the quiz to find out!
How do muscarinic acetylcholine...
10/23/2024
Psych Congress NP Institute
pop quiz
Quiz
Esketamine Dosing Schedule for Treatment-Resistant Depression
10/01/2024
During the induction and maintenance phases of esketamine treatment, how frequently should the medication be administered to treat TRD? Take the quiz to test your psychopharmacology knowledge.
During the induction and maintenance phases of esketamine treatment, how frequently should the medication be administered to treat TRD? Take the quiz to test your psychopharmacology knowledge.
During the induction and...
10/01/2024
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Telehealth Versus In-Person Psychiatric Care
09/19/2024
Do you know what the data from randomized control trials say?
Do you know what the data from randomized control trials say?
Do you know what the data from...
09/19/2024
Psych Congress Network
How many ADHD prescriptions are affected by the med shortage?
Quiz
How many ADHD prescriptions are affected by the med shortage?
09/17/2024
Take a quick poll on your recent prescribing practices!
Take a quick poll on your recent prescribing practices!
Take a quick poll on your recent...
09/17/2024
Psych Congress Network
Symptom Reduction in Bipolar Disorder Treatment
Expert Insights Quiz
Symptom Reduction in Bipolar Disorder Treatment
09/13/2024
Test your knowledge
Test your knowledge
Test your knowledge
09/13/2024
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
CDC/AAP Treatment Guidelines for Pediatric ADHD
09/11/2024
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
09/11/2024
Psych Congress Network
A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
Quiz
Considerations When Prescribing Deutetrabenazine for Tardive Dyskinesia
09/10/2024
Put your clinical knowledge to the test with this quiz!
Put your clinical knowledge to the test with this quiz!
Put your clinical knowledge to...
09/10/2024
Psych Congress Network
A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
Quiz
Considerations When Prescribing Deutetrabenazine for Tardive Dyskinesia
09/10/2024
Put your clinical knowledge to the test with this quiz!
Put your clinical knowledge to the test with this quiz!
Put your clinical knowledge to...
09/10/2024
Psych Congress Network

Recent FDA Updates

The US Food and Drug Administration headquarters sign.
FDA Approves Donanemab for Early Alzheimer Disease Treatment
07/02/2024
The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.
The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.
The US Food and Drug...
07/02/2024
Psych Congress Network
Video Game Treatment for Adults With ADHD Cleared by FDA
News
Video Game Treatment for Adults With ADHD Cleared by FDA
07/02/2024
AKL-T01 is indicated for adults with primarily inattentive or combined-type ADHD who have a demonstrated attention issue.
AKL-T01 is indicated for adults with primarily inattentive or combined-type ADHD who have a demonstrated attention issue.
AKL-T01 is indicated for adults...
07/02/2024
Psych Congress Network
FDA approval featuring craig chepke
News
FDA Approves First Schizophrenia Treatment in Over 3 Decades
09/27/2024
The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.
The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.
The US Food and Drug...
09/27/2024
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Expert Insights

Jonathan Meyer, MD
Videos
Unpacking Negative Symptoms, Medication Adverse Effects, and Emerging Schizophrenia Treatments
11/11/2024
Jonathan Meyer, MD, offers his clinical insights on schizophrenia management.
Jonathan Meyer, MD, offers his clinical insights on schizophrenia management.
Jonathan Meyer, MD, offers his...
11/11/2024
Psych Congress Network
Thomas L. Schwartz, MD
Q&As
How Psychiatrists Can Address Sleep-Wake Disorders Effectively
11/09/2024
Thomas L. Schwartz, MD, shares exclusive insights from his session on sleep-wake issues presented at the 2024 NEI Fall Congress.
Thomas L. Schwartz, MD, shares exclusive insights from his session on sleep-wake issues presented at the 2024 NEI Fall Congress.
Thomas L. Schwartz, MD, shares...
11/09/2024
Psychiatry & Behavioral Health
Desiree Matthews
Schizophrenia Conference Insights
New Class of Medication Offers Innovative Treatment for Schizophrenia Symptoms
11/07/2024
Watch these exclusive insights with Desiree Matthews, PMHNP-BC, to learn how this novel treatment could reshape the landscape of care for adults living with schizophrenia.
Watch these exclusive insights with Desiree Matthews, PMHNP-BC, to learn how this novel treatment could reshape the landscape of care for adults living with schizophrenia.
Watch these exclusive insights...
11/07/2024
Psych Congress Network
Marc Agronin
Videos
Implementing Alzheimer Disease Prevention Practices
11/02/2024
Dr Marc Agronin discusses some easy prevention strategies for Alzheimer disease following his Psych Congress 2024 session "A New Era for Alzheimer’s Disease: Prevention, Early Diagnosis, Effective Intervention."
Dr Marc Agronin discusses some easy prevention strategies for Alzheimer disease following his Psych Congress 2024 session "A New Era for Alzheimer’s Disease: Prevention, Early Diagnosis, Effective Intervention."
Dr Marc Agronin discusses some...
11/02/2024
Psych Congress Network
Michelle Martel, PhD
Q&As
When It Comes to ADHD in Women, There's Still So Much to Learn
10/31/2024
Michelle Martel, PhD, shares insights from her session on ADHD in women presented at the 2024 Psych Congress.
Michelle Martel, PhD, shares insights from her session on ADHD in women presented at the 2024 Psych Congress.
Michelle Martel, PhD, shares...
10/31/2024
Psych Congress Network

Live Meetings

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement